Affilin^® Technology

Scil Proteins focuses on the development of biotherapeutics applying its proprietary Affilin^® technology for its own pipeline as well as in collaboration with pharmaceutical partners. Affilin^® molecules are based on the human Ubiquitin scaffold and engineered to generate de-novo binding affinity towards disease-relevant targets. The platform allows the generation of agonistic or antagonistic binding molecules, their fusion to effector molecules or multispecific designs. Thus, Affilin^® molecules present an attractive alternative or complement to conventional antibody formats, broadening the application space of biotherapeutics.